EMEA Point-Of-Care Diagnostics Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), By End-use (Clinics, Home), By Region (Europe, MEA), And Segment Forecasts

EMEA point-of-care diagnostics Market Trends

The EMEA point-of-care (POC) diagnostics market size was estimated at USD 14.08 billion in 2024 and is projected to reach USD 23.13 billion by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This market emphasizes rapid diagnostic solutions designed for near-patient testing, enabling timely clinical decisions and improved healthcare outcomes. POC diagnostics in Europe, Middle East, and Africa (EMEA) region span a range of applications, including infectious disease detection, cardiovascular monitoring, blood glucose testing, pregnancy screening, and other critical areas that require swift and reliable results. These solutions are increasingly utilized across hospitals, clinics, and home care settings, reducing the need for centralized laboratory testing. 

The market is supported by advancements in portable devices, user-friendly testing kits, and digital connectivity that allow seamless data sharing and integration with healthcare systems. Growing demand for decentralized healthcare, along with efforts to improve diagnostic access in remote areas across Europe, the Middle East, and Africa, is encouraging adoption. Technological innovations, such as microfluidics, lateral flow assays, and molecular diagnostics at the point of care, are reshaping the landscape by enabling faster turnaround times and expanding the range of testable conditions. For instance, in June 2023, Sysmex introduced the first point-of-care antimicrobial susceptibility testing system in Europe. Using proprietary microfluidic technology, this system delivers results in as little as 30 minutes, supporting rapid identification of resistant pathogens and optimizing treatment decisions in clinical settings.

Furthermore, favorable healthcare initiatives and increased awareness of early disease detection are driving investments in POC technologies across the Europe, Middle East, and Africa (EMEA) region. Public and private sector collaborations are strengthening diagnostic networks and accelerating the adoption of cost-effective, rapid testing solutions. The growing focus on digital health integration, supported with telemedicine and connected diagnostic platforms, is expected to further improve patient management and expand the reach of POC diagnostics in both developed and emerging markets within the region.

These innovations are transforming the global high throughput screening landscape by enabling faster, more precise, and cost-effective drug discovery solutions. The integration of AI-driven analytics, microfluidics, and advanced 3D cell models is improving the reliability of screening outcomes and streamlining decision-making. With pharmaceutical and biotechnology companies focusing on efficient lead identification and early-stage validation, these advancements are expected to strengthen drug development pipelines and accelerate time-to-market for novel therapeutics in the coming years.

Market Concentration & Characteristics

Innovation in point-of-care diagnostics within EMEA is strong, driven by the need for rapid, accurate, and decentralized testing solutions. Advancements in molecular POC platforms, microfluidics, and AI-driven result interpretation are enhancing diagnostic speed and reliability. The adoption of connected devices, real-time data analytics, and integration with telemedicine platforms reflects the market’s shift toward patient-centric and data-enabled healthcare solutions. These innovations aim to streamline testing processes while improving accessibility and clinical outcomes.

Mergers, acquisitions, and strategic collaborations are prominent as diagnostic firms partner with technology developers and research institutions to expand their product portfolios. Companies are focusing on co-developing advanced POC assays and strengthening distribution networks across Europe, the Middle East, and Africa. Partnerships to integrate connectivity features and expand product commercialization are also contributing to a competitive and consolidated market landscape.

Regulatory frameworks are significantly influencing the development of the EMEA POC diagnostics market. Agencies such as the European Medicines Agency (EMA) and national regulatory bodies emphasize stringent validation, safety, and performance requirements for diagnostic products. Compliance with quality standards, particularly in decentralized testing and home-use devices, is critical for market entry and reimbursement. Evolving digital health and telemedicine integration guidelines are creating new opportunities for connected POC solutions.

Product development is dynamic, with companies focusing on creating multifunctional POC devices capable of testing multiple parameters from a single sample. There is an increasing trend toward compact, portable, and smartphone-compatible diagnostic solutions designed for quick turnaround times. Developers are also prioritizing the integration of digital reporting tools and cloud-based platforms to enhance result accessibility and facilitate clinical decision-making.

Regional growth strategies are gaining traction as companies target underserved areas in the Middle East and Africa while maintaining strong presence in Europe. Efforts to improve testing availability through affordable devices and local partnerships are expanding the reach of POC diagnostics. With healthcare systems in EMEA increasingly prioritizing decentralized testing, these initiatives are expected to drive significant market penetration and adoption in both developed and emerging markets.

Product Insights

Glucose testing segment accounted for the largest market share of 32.8% in 2024, underpinned by its pivotal role in diabetes management and self-monitoring. Portable glucometers and continuous glucose monitoring (CGM) devices with user‑friendly interfaces and digital connectivity are widely adopted across clinical and home settings. The rising prevalence of diabetes across Europe, the Middle East, and Africa has heightened demand for real-time glucose tracking to help patients and healthcare providers better manage treatment and avoid complications.

A recent innovation underscores this trend: in July 2024, Roche received CE Mark approval for its Accu‑Chek SmartGuide CGM solution, which offers real-time glucose readings every five minutes and integrates AI‑based predictive algorithms that forecast hypoglycemia risk up to 30 minutes in advance and glucose trends over the next two hours-empowering proactive diabetes care in EMEA markets  Continuous improvements in CGM technology-including extended sensor wear time, predictive analytics, and seamless connectivity-are expected to reinforce the glucose testing segment’s dominance and expand its accessibility in both developed and emerging regions across EMEA.

The cancer markers segment is projected to grow at the fastest CAGR during the forecast period, driven by the rising incidence of cancer and the demand for early and accurate detection methods to improve patient outcomes. Molecular point-of-care platforms equipped with multiplex PCR and microfluidic technologies are enhancing the speed and sensitivity of cancer marker detection, supporting real-time diagnosis and therapy selection. Growing research initiatives and integration of biomarker-based testing into connected diagnostic devices are expected to accelerate adoption across oncology practices in the EMEA region, making cancer markers a critical growth driver within the point-of-care diagnostics market.

End-use Insights

Clinics segment held the largest market share in 2024 due to the rising prevalence of chronic and infectious diseases, which require rapid and accurate diagnostic solutions for timely patient management. As the first point of contact for patients, clinics rely heavily on point-of-care diagnostics to deliver immediate results and initiate appropriate treatment plans. The growing establishment of rapid clinics, offering low-cost primary healthcare services with extended (24/7) operating hours, has further strengthened the demand for POC testing in this segment.

Favorable government policies in the EMEA region, including streamlined approval processes for innovative diagnostic devices, have supported the faster adoption of POC technologies within clinics. The integration of connected devices and digital health solutions allows these facilities to enhance patient care and improve operational efficiency. With increasing healthcare investments and the push for decentralized diagnostic models, clinics are expected to maintain their dominant position in the Europe, Middle East, and Africa (EMEA) point-of-care diagnostics market throughout the forecast period.

Home healthcare facilities segment is projected to grow at a CAGR of 7.4% over the forecast period, supported by the increasing incidence of chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders that require continuous monitoring. Point-of-care diagnostics offer patients a convenient and cost-effective way to manage their health without frequent hospital or clinic visits. Portable and user-friendly devices, including glucose monitors, blood pressure testing kits, and rapid home tests for infectious diseases, are driving adoption in this segment.

Integrating digital health technologies, such as mobile applications, wearable sensors, and telemedicine platforms, has further enhanced the utility of home-based diagnostics by enabling real-time data sharing with healthcare providers. This connectivity allows for timely interventions and better disease management, improving patient outcomes. With growing patient preference for home-based care and ongoing innovations in connected diagnostic solutions, the home healthcare segment is expected to witness steady expansion within the Europe, Middle East, and Africa point-of-care diagnostics market

Regional Insights

Germany Point-Of-Care Diagnostics Market Trends

Germany shows strong growth in the EMEA point-of-care diagnostics market, supported by its advanced healthcare infrastructure and rising demand for rapid diagnostic solutions. The Germany point-of-care diagnostics market accounted for 15.7% of the share in 2024, driven by the increasing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders that require timely and accurate results. The convenience and immediacy of POC testing enable healthcare providers to make faster clinical decisions, improving patient outcomes and reducing the reliance on traditional laboratory services.

Moreover, Germany’s supportive government policies and initiatives are promoting the adoption of POC diagnostics. Funding for research and development, subsidies for healthcare providers, and public awareness campaigns are fostering the use of connected and portable testing devices. With ongoing innovations in molecular POC platforms and digital health integration, Germany is expected to maintain its strong position in the Europe, Middle East, and Africa point-of-care diagnostics market throughout the forecast period.

UK Point-Of-Care Diagnostics Market Trends

The UK point-of-care diagnostics market is expected to emerge as the fastest-growing country during the forecast period. This growth is driven by strong healthcare policies supporting decentralized testing and the increasing demand for rapid diagnostic solutions across clinics, hospitals, and home care settings. National programs focused on early detection of chronic and infectious diseases, combined with the integration of digital health platforms, are accelerating the adoption of POC devices and enhancing patient care delivery.

Notably, in April 2025, the NHS introduced N‑Tidal Diagnose, the first non-spirometry AI-based point-of-care test for COPD in the UK. Approved under EU Medical Device Regulations, this tool delivers results in just five minutes, offering a faster and more accessible alternative to traditional lung function tests and significantly reducing diagnostic waiting times. This innovation highlights the UK’s ongoing efforts to strengthen its POC diagnostics landscape and reinforces its position as one of the fastest-growing markets in the EMEA region.

South Africa Point-Of-Care Diagnostics Market Trends

South Africa shows robust growth in the Europe, Middle East, and Africa point-of-care diagnostics market, supported by its high burden of infectious diseases and ongoing public health initiatives aimed at improving early detection. The country’s healthcare system is increasingly adopting rapid and portable testing solutions to address challenges related to HIV, tuberculosis, and diabetes. The growing demand for decentralized healthcare services and the expansion of community-based diagnostic programs are further driving the use of POC devices across primary care facilities.

For instance, in February 2025, South Africa launched an 11‑million USD “Closing 1.1 Million HIV Treatment Gap” campaign to identify and treat individuals who are aware of their HIV-positive status but not yet on antiretroviral therapy. This initiative leverages point-of-care HIV testing in community and clinic settings to rapidly close the treatment gap-mirroring key trends in the EMEA POC diagnostics market around decentralized testing and integration of rapid diagnostics into national public health strategies.

UAE Point-Of-Care Diagnostics Market Trends

The UAE point-of-care diagnostics market is expected to emerge as one of the fastest-growing countries during the forecast period, underpinned by its robust healthcare infrastructure, rising chronic disease burden, and government-led initiatives promoting rapid testing. National programs to expand access to decentralized diagnostics across clinics, hospitals, and community health facilities drive strong market adoption. The prevalence of conditions such as diabetes, cardiovascular disease, and respiratory infections is accelerating demand for convenient and connected POC solutions.

Notably, in June 2025, researchers at NYU Abu Dhabi developed the Radially Compartmentalised Paper Chip (RCP‑Chip)-a portable, paper-based diagnostic tool capable of detecting infectious diseases in under 10 minutes, requiring no laboratory infrastructure or trained personnel. This innovation embodies the core principles of point-of-care diagnostics by enabling fast, affordable, and field‑deployable testing solutions, aligning with UAE’s broader strategy to integrate rapid diagnostics into its public health framework. These developments and ongoing investments in digital health platforms and mobile health solutions position the UAE as a key growth driver in the EMEA POC diagnostics landscape.

Key EMEA Point-of-Care Diagnostics Company Insights

Key players in the EMEA point-of-care diagnostics market are focusing on product innovation, regulatory approvals, and collaborations to expand their presence. Strategies include developing portable and connected devices for rapid testing, integrating digital health platforms for real-time data sharing, and promoting decentralized diagnostic models to improve accessibility across clinical and home care settings.

Recent Developments

• In July 2025, NHS England announced a two‑year pilot that will offer the capsule sponge “sponge‑on‑a‑string” test (EndoSign; Cyted Health) through selected high‑street pharmacies with Boots in London and the East Midlands. Delivered in under 10 minutes, the swallow‑and‑retrieve test collects oesophageal cells to detect Barrett’s oesophagus, a precursor to oesophageal cancer. The programme aims to move diagnostic care closer to the community, cut reliance on endoscopy capacity, and support earlier detection-illustrating the expansion of decentralized, patient‑centric point‑of‑care approaches in the EMEA diagnostics market.

• In March 2025, major UK retailers, including Boots, launched a new generation of finger-prick lateral flow tests (LFTs) designed to detect biomarkers such as vitamin D, iron, cholesterol, and influenza from a single blood sample. Early-stage clinical trials are also exploring their application in diagnosing stroke and early sepsis outside traditional laboratory settings. This development underscores the expanding clinical scope of LFTs and their role in supporting decentralized, rapid diagnostics within the EMEA point-of-care diagnostics market.

• In July 2024, EKF Diagnostics launched the Biosen C‑Line, an upgraded benchtop glucose and lactate analyzer designed for point-of-care settings across the EMEA region. The device features advanced connectivity options through EKF Link middleware, enabling seamless and secure integration with hospital and laboratory IT systems. This development enhances the speed and reliability of glucose and lactate testing, aligning with the market trend toward connected and efficient POC diagnostic solutions.

EMEA Point-of-Care Diagnostics Market Report Scope

EMEA Point-of-Care Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the EMEA point-of-care diagnostics market based on product, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Glucose Testing

  • Hb1Ac Testing

  • Coagulation Testing

  • Fertility/ Pregnancy

  • Infectious Disease

    • HIV POC

    • Clostridium Difficile POC

    • HBV POC

    • Pneumonia or Streptococcus Associated Infections

    • Respiratory Syncytial Virus (RSV) POC

    • HPV POC

    • Influenza/ Flu POC

    • HCV POC

    • MRSA POC

    • TB and Drug-resistant TB POC

    • HSV POC

    • COVID-19

    • Other Infectious Diseases

  • Cardiac Markers

  • Thyroid Stimulating Hormone

  • Hematology

  • Primary Care Systems

  • Decentralized Clinical Chemistry

  • Feces

  • Lipid Testing

  • Cancer Marker

  • Blood Gas/ Electrolytes

  • Ambulatory Chemistry

  • Drug of Abuse (DOA) Testing

  • Autoimmune Diseases

  • Urinalysis/ Nephrology

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Clinics

    • Pharmacy & Retail Clinics

    • Physician Office

    • Urgent Care Clinics

  • Hospitals

  • Home

  • Assisted Living Healthcare Facilities

  • Laboratory

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait